SCHEMBL1167413

SCHEMBL1167413

O=C(O)C=Cc1cccc(C(F)(F)F)c1F

nearest known ligand 0.56

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
NFKB1 P19838 2/20 0.56
MAOB P27338 9/20 0.51
CA1 P00915 1/20 0.47
CA2 P00918 1/20 0.47
CA4 P22748 1/20 0.47
P4HB P07237 1/20 0.47
ABCG2 Q9UNQ0 1/20 0.47
MAOA P21397 1/20 0.43
BACE1 P56817 1/20 0.43
KDM4E B2RXH2 1/20 0.43
MAPT P10636 2/20 0.43
MEN1 O00255 1/20 0.43
LMNA P02545 1/20 0.43
KMT2A Q03164 1/20 0.43
MIF P14174 1/20 0.42
HTT P42858 1/20 0.41
PARP1 P09874 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL700920 1.00 NFKB1 (0.56) NFKB1MAOBCA1CA2CA4
Hydrochloric Acid SCHEMBL6821159 0.98 NFKB1 (0.54) NFKB1MAOBCA1CA2CA4
SCHEMBL6821155 0.85 NFKB1 (0.54) NFKB1MAOBP4HBABCG2MAOA
SCHEMBL6821153 0.85 NFKB1 (0.54) NFKB1MAOBP4HBABCG2MAOA
SCHEMBL1167281 0.85 MIF (0.47) NFKB1MAOBCA1CA2CA4
SCHEMBL1167283 0.85 MIF (0.47) NFKB1MAOBCA1CA2CA4
SCHEMBL8055837 0.84 NFKB1 (0.77) NFKB1MAOBCA1CA2CA4
SCHEMBL29365331 0.84 NFKB1 (0.77) NFKB1MAOBCA1CA2CA4
SCHEMBL82267 0.84 NFKB1 (0.77) NFKB1MAOBCA1CA2CA4
SCHEMBL82266 0.84 NFKB1 (0.77) NFKB1MAOBCA1CA2CA4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2242743-B1 AMINOPYRAZOLE DERIVATIVES ACTELION PHARMACEUTICALS LTD (CH) 2013-08-21 EP disclosed
US-8288419-B2 Aminopyrazole derivatives ACTELION PHARMACEUTICALS, LTD (CH) 2012-10-16 US disclosed
US-20110034516-A1 AMINOPYRAZOLE DERIVATIVES ACTELION (CH) 2011-02-10 US disclosed
EP-2242743-A1 AMINOPYRAZOLE DERIVATIVES Actelion Pharmaceuticals Ltd. (CH) 2010-10-27 EP disclosed
WO-2009077954-A1 AMINOPYRAZOLE DERIVATIVES ACTELION PHARMACEUTICALS LTD (CH) 2009-06-25 WO disclosed
WO-2004046122-A2 BENZOXAZOLE, BENZTHIAZOLE AND BENZIMIDAZOLE ACID DERIVATIVES AND THEIR USE AS HEPARANASE INHIBITORS OXFORD GLYCOSCIENCES (UK) LTD (GB) 2004-06-03 WO disclosed
EP-1091958-A1 SALTS OF PAROXETINE SMITHKLINE BEECHAM PLC (GB) 2001-04-18 EP disclosed
WO-2000001692-A1 SALTS OF PAROXETINE SMITHKLINE BEECHAM PLC (GB) 2000-01-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110034516-A1 AMINOPYRAZOLE DERIVATIVES CYP3A43, CYP1A2, CYP3A5 NFKB1 2598/4885MAOB 253/4885CA1 4355/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.